The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
(((2-(3-((3-Fluoro-4-methoxyphenyl)carbamoyl)phenyl)-thieno[2,3-d]pyrimidin-4-yl)amino)methylene)bis-(phosphonic acid) ID: ALA4577077
PubChem CID: 153290116
Max Phase: Preclinical
Molecular Formula: C21H19FN4O8P2S
Molecular Weight: 568.42
Molecule Type: Unknown
Associated Items:
Names and Identifiers Canonical SMILES: COc1ccc(NC(=O)c2cccc(-c3nc(NC(P(=O)(O)O)P(=O)(O)O)c4ccsc4n3)c2)cc1F
Standard InChI: InChI=1S/C21H19FN4O8P2S/c1-34-16-6-5-13(10-15(16)22)23-19(27)12-4-2-3-11(9-12)17-24-18(14-7-8-37-20(14)25-17)26-21(35(28,29)30)36(31,32)33/h2-10,21H,1H3,(H,23,27)(H,24,25,26)(H2,28,29,30)(H2,31,32,33)
Standard InChI Key: XPPGEOUCUMGOGK-UHFFFAOYSA-N
Molfile:
RDKit 2D
37 40 0 0 0 0 0 0 0 0999 V2000
5.4105 -12.5866 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
6.1202 -12.1772 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.1174 -11.3545 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
5.4087 -10.9492 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.7025 -12.1776 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.6992 -11.3611 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.9216 -11.1119 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.4443 -11.7745 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.9269 -12.4330 0.0000 S 0 0 0 0 0 0 0 0 0 0 0 0
5.4061 -10.1320 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
6.1125 -9.7212 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.1099 -8.9040 0.0000 P 0 0 0 0 0 0 0 0 0 0 0 0
6.8215 -10.1275 0.0000 P 0 0 0 0 0 0 0 0 0 0 0 0
5.4008 -8.4977 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
6.8241 -10.9447 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
7.5279 -9.7166 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
6.6861 -8.3205 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
6.8966 -9.1129 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
6.1454 -10.4419 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
6.8250 -12.5839 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.8250 -13.4022 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
7.5325 -13.8096 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
8.2405 -13.3998 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
8.2366 -12.5784 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
7.5285 -12.1747 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
8.9422 -12.1662 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
9.6520 -12.5712 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
8.9381 -11.3490 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
10.3576 -12.1590 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11.0656 -12.5689 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11.7707 -12.1574 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11.7670 -11.3393 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11.0523 -10.9345 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.3501 -11.3484 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11.0452 -10.1174 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
12.4721 -10.9262 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
13.1824 -11.3302 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5 1 1 0
1 2 2 0
2 3 1 0
3 4 2 0
4 6 1 0
5 6 2 0
6 7 1 0
7 8 2 0
8 9 1 0
9 5 1 0
4 10 1 0
10 11 1 0
11 12 1 0
11 13 1 0
12 14 2 0
13 15 1 0
13 16 2 0
12 17 1 0
12 18 1 0
13 19 1 0
20 21 2 0
21 22 1 0
22 23 2 0
23 24 1 0
24 25 2 0
25 20 1 0
2 20 1 0
24 26 1 0
26 27 1 0
26 28 2 0
27 29 1 0
29 30 2 0
30 31 1 0
31 32 2 0
32 33 1 0
33 34 2 0
34 29 1 0
33 35 1 0
32 36 1 0
36 37 1 0
M END Associated Targets(Human) Associated Targets(non-human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 568.42Molecular Weight (Monoisotopic): 568.0383AlogP: 3.81#Rotatable Bonds: 8Polar Surface Area: 191.20Molecular Species: ACIDHBA: 8HBD: 6#RO5 Violations: 2HBA (Lipinski): 12HBD (Lipinski): 6#RO5 Violations (Lipinski): 3CX Acidic pKa: 0.88CX Basic pKa: 4.10CX LogP: 1.03CX LogD: -1.48Aromatic Rings: 4Heavy Atoms: 37QED Weighted: 0.17Np Likeness Score: -1.72
References 1. Lacbay CM, Waller DD, Park J, Gómez Palou M, Vincent F, Huang XF, Ta V, Berghuis AM, Sebag M, Tsantrizos YS.. (2018) Unraveling the Prenylation-Cancer Paradox in Multiple Myeloma with Novel Geranylgeranyl Pyrophosphate Synthase (GGPPS) Inhibitors., 61 (15): [PMID:30016091 ] [10.1021/acs.jmedchem.8b00886 ] 2. Lee HF, Lacbay CM, Boutin R, Matralis AN, Park J, Waller DD, Guan TL, Sebag M, Tsantrizos YS.. (2022) Synthesis and Evaluation of Structurally Diverse C-2-Substituted Thienopyrimidine-Based Inhibitors of the Human Geranylgeranyl Pyrophosphate Synthase., 65 (3.0): [PMID:35077178 ] [10.1021/acs.jmedchem.1c01913 ]